Compare · PSTV vs SYK
PSTV vs SYK
Side-by-side comparison of PLUS THERAPEUTICS Inc. (PSTV) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PSTV and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 4222.4x PSTV ($26.6M).
- Both names hit the wire about 8 times in the past 4 weeks.
- SYK has more recent analyst coverage (25 ratings vs 3 for PSTV).
- Company
- PLUS THERAPEUTICS Inc.
- Stryker Corporation
- Price
- $3.90+8.79%
- $294.69+0.46%
- Market cap
- $26.6M
- $112.48B
- 1M return
- -6.47%
- -
- 1Y return
- -74.64%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 8
- 8
- Recent ratings
- 3
- 25
PLUS THERAPEUTICS Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest PSTV
- PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Chief Financial Officer Sims Andrew John Hugh Macintyre converted options into 2,985 shares, increasing direct ownership by 30% to 12,926 units (SEC Form 4)
- Director Guse Kyle converted options into 921 shares, increasing direct ownership by 100% to 1,843 units (SEC Form 4)
- Chief Executive Officer Hedrick Marc H converted options into 16,439 shares, increasing direct ownership by 37% to 60,922 units (SEC Form 4)
- Director Van Es-Johansson An converted options into 921 shares, increasing direct ownership by 100% to 1,843 units (SEC Form 4)
- Director Andrews Ronald Asbury converted options into 921 shares, increasing direct ownership by 100% to 1,843 units (SEC Form 4)
- Director Hawkins Richard J converted options into 921 shares, increasing direct ownership by 60% to 2,450 units (SEC Form 4)
- Director Clowes Howard converted options into 921 shares, increasing direct ownership by 46% to 2,902 units (SEC Form 4)
- SEC Form D filed by PLUS THERAPEUTICS Inc.
- PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)